Mauri Giovanni, Hegedüs Laszlo, Bandula Steven, Cazzato Roberto Luigi, Czarniecka Agnieszka, Dudeck Oliver, Fugazzola Laura, Netea-Maier Romana, Russ Gilles, Wallin Göran, Papini Enrico
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Division of Interventional Radiology, European Institute of Oncology, IRCCS, Milan, Italy.
Eur Thyroid J. 2021 Jun;10(3):185-197. doi: 10.1159/000516469. Epub 2021 May 25.
The growing detection of papillary thyroid microcarcinomas (PTMCs) is paralleled by an increase in surgical procedures. Due to the frequent indolent nature, cost, and risk of surgery, active surveillance (AS) and ultrasound-guided minimally invasive treatments (MITs) are in suitable cases of incidental PTMC proposed as alternatives to thyroidectomy. Surgery and radioiodine are the established treatments for relapsing cervical differentiated thyroid carcinoma (DTC) metastases. But radioiodine refractoriness, risk of surgical complications, adverse influence on quality of life, or declining repeat surgery have led to AS and MIT being considered as alternatives for slow-growing DTC nodal metastases. Also, for distant radioiodine-refractory metastases not amenable to surgery, MIT is proposed as part of a multimodality therapeutic approach. The European Thyroid Association and the Cardiovascular and Interventional Radiological Society of Europe commissioned these guidelines for the appropriate use of MIT. Based on a systematic PubMed search, an evidence-based approach was applied, and both knowledge and practical experience of the panelists were incorporated to develop the manuscript and the specific recommendations. We recommend that when weighing between surgery, radioiodine, AS, or MIT for DTC, a multidisciplinary team including members with expertise in interventional radiology assess the demographic, clinical, histological, and imaging characteristics for appropriate selection of patients eligible for MIT. Consider TA in low-risk PTMC patients who are at surgical risk, have short life expectancy, relevant comorbidities, or are unwilling to undergo surgery or AS. As laser ablation, radiofrequency ablation, and microwave ablation are similarly safe and effective thermal ablation (TA) techniques, the choice should be based on the specific competences and resources of the centers. Use of ethanol ablation and high-intensity focused ultrasound is not recommended for PTMC treatment. Consider MIT as an alternative to surgical neck dissection in patients with radioiodine refractory cervical recurrences who are at surgical risk or decline further surgery. Factors that favor MIT are previous neck dissection, presence of surgical complications, small size metastases, and <4 involved latero-cervical lymph nodes. Consider TA among treatment options in patients with unresectable oligometastatic or oligoprogressive distant metastases to achieve local tumor control or pain palliation. Consider TA, in combination with bone consolidation and external beam radiation therapy, as a treatment option for painful bone metastases not amenable to other established treatments.
甲状腺微小乳头状癌(PTMC)检出率的不断上升,伴随着手术量的增加。由于其常见的惰性特征、成本以及手术风险,对于偶然发现的PTMC,在合适的病例中,主动监测(AS)和超声引导下的微创治疗(MIT)被提议作为甲状腺切除术的替代方案。手术和放射性碘是复发性颈部分化型甲状腺癌(DTC)转移灶的既定治疗方法。但是放射性碘难治性、手术并发症风险、对生活质量的不利影响或再次手术次数的减少,导致AS和MIT被视为生长缓慢的DTC淋巴结转移的替代方案。此外,对于无法手术的远处放射性碘难治性转移灶,MIT被提议作为多模式治疗方法的一部分。欧洲甲状腺协会和欧洲心血管与介入放射学会委托制定这些关于MIT合理使用的指南。基于PubMed系统检索,采用循证方法,并纳入专家小组成员的知识和实践经验来撰写本手稿及制定具体建议。我们建议,在为DTC权衡手术、放射性碘、AS或MIT时,一个包括介入放射学专家的多学科团队应评估人口统计学、临床、组织学和影像学特征,以适当选择适合MIT的患者。对于手术风险高、预期寿命短、有相关合并症或不愿接受手术或AS的低风险PTMC患者,考虑热消融(TA)。由于激光消融、射频消融和微波消融是同样安全有效的热消融技术,选择应基于各中心的具体能力和资源。不建议使用乙醇消融和高强度聚焦超声治疗PTMC。对于有手术风险或拒绝进一步手术的放射性碘难治性颈部复发患者,考虑将MIT作为手术颈部清扫的替代方案。有利于MIT的因素包括既往颈部清扫、存在手术并发症、转移灶小以及颈侧淋巴结受累少于4个。对于无法切除的寡转移或寡进展性远处转移患者,考虑将TA作为治疗选择之一,以实现局部肿瘤控制或缓解疼痛。对于不适合其他既定治疗的疼痛性骨转移,考虑将TA与骨巩固和外照射放疗联合作为治疗选择。